Introduction {#section5-2050312119838417}
============

The INtubation-SURfactant-Extubation (INSURE) technique has been shown to decrease the incidence of subsequent need for mechanical ventilation and chronic lung disease (CLD).^[@bibr1-2050312119838417][@bibr2-2050312119838417][@bibr3-2050312119838417][@bibr4-2050312119838417][@bibr5-2050312119838417][@bibr6-2050312119838417][@bibr7-2050312119838417]--[@bibr8-2050312119838417]^ However, extremely premature infants have a higher risk of subsequent need for intubation and mechanical ventilation, and continuous positive airway pressure (CPAP) failure itself has been associated with higher rates of mortality and CLD.^[@bibr9-2050312119838417]^ Non-synchronized nasal intermittent positive pressure ventilation (NIPPV) and flow-synchronized nasal intermittent positive pressure ventilation (SNIPPV) have been reported to decrease the rate of INSURE failure compared with nasal continuous positive airway pressure (NCPAP). The reported rates of INSURE failure were 15% to 40% with NCPAP,^[@bibr1-2050312119838417][@bibr2-2050312119838417][@bibr3-2050312119838417][@bibr4-2050312119838417][@bibr5-2050312119838417][@bibr6-2050312119838417][@bibr7-2050312119838417]--[@bibr8-2050312119838417]^,^[@bibr10-2050312119838417][@bibr11-2050312119838417][@bibr12-2050312119838417]--[@bibr13-2050312119838417]^ 11.4% to 17% with NIPPV,^[@bibr10-2050312119838417][@bibr11-2050312119838417]--[@bibr12-2050312119838417]^ and 6.1% with flow-SNIPPV.^[@bibr13-2050312119838417]^ Flow-SNIPPV has been reported to decrease breathing effort because of the effect in improving ventilatory--patient interactions compared with NIPPV.^[@bibr14-2050312119838417]^ Non-invasive neurally adjusted ventilatory assist (NIV-NAVA), another type of SNIPPV, is also available for infants, and NIV-NAVA has been shown to improve patient--ventilator interactions even in infants with large air leak compared with using flow-SNIPPV.^[@bibr15-2050312119838417]^

No previous studies appear to have evaluated the efficacy of NIV-NAVA after INSURE. What is the rate of INSURE failure when NIV-NAVA is used after INSURE? Furthermore, can preterm infants safely undergo NIV-NAVA soon after birth? Given these important questions, the aim of this study was to evaluate the efficacy and safety of NIV-NAVA used after INSURE for respiratory distress syndrome (RDS) in infants at 28 (0/7) to 33 (6/7) weeks of gestation.

Methods {#section6-2050312119838417}
=======

We conducted a prospective observational study without a control group between April 2017 and October 2018. Inborn preterm infants at 28 (0/7) to 33 (6/7) weeks of gestation with RDS who were admitted to our neonatal intensive care unit were included. We performed CPAP using a face mask by Jackson Rees circuit for spontaneously breathing infants with respiratory distress, tachypnea, or oxygen requirement. RDS in the study was defined as follows: the presence of respiratory distress, tachypnea, oxygen requirement (fraction of inspired oxygen (FiO~2~) \>0.3 to maintain SpO~2~ \>89%), and stable microbubble counts ⩽10 on gastric aspirate.

Exclusion criteria were as follows: surfactant administration at \>2 h after birth, asphyxia (5-min Apgar score \<7), presence of amniotic fluid contaminated by meconium, presence of major congenital anomalies, prolonged premature rupture of membranes (\>120 h), small for gestational age, or unavailability of a respirator for NIV-NAVA.

Soon after the diagnosis of RDS, we performed transient intubation for surfactant administration. Surfacten^®^ (Mitsubishi-Tokyo Pharma, Osaka, Japan) was administered endotracheally at 120 mg/kg, followed by manual ventilation by Jackson Rees circuit. The infant was then extubated in the presence of good spontaneous breathing and oxygenation. After extubation, the infant was treated with NIV-NAVA for at least 24 h using a SERVO-n neonatal ventilator (Maquet Critical Care AB, Solna, Sweden) via a Miniflow adaptor and nasal prongs or masks (Medin Medical Innovations, Olching, Germany) as appropriate for weight. A special electrode-equipped catheter to detect electrical activity of the diaphragm (Edi) (Edi catheter; Maquet Critical Care AB) was inserted for all infants. Initial settings for NIV-NAVA were as follows: positive end expiratory pressure (PEEP): 6 cmH~2~O, neurally adjusted ventilatory assist (NAVA) level: 2.0, and apnea time: 5 s. NAVA level was adjusted to maintain Edi maximum \<15 µV.

Re-intubation and mechanical ventilation were performed for infants showing INSURE failure, defined as meeting ⩾1 of the following categories: (1) FiO~2~ requirement \>0.4 to maintain SpO~2~ \>89%, (2) respiratory acidosis: pH \<7.25 and partial pressure of carbon dioxide (pCO~2~) \>59 mm Hg, and (3) severe apnea: \>6 episodes per 12 h of apnea or \>2 episodes per 24 h of apnea requiring bag-and-mask ventilation.

The primary outcome of the study was the requirement for mechanical ventilation within 5 days. Secondary outcomes were duration of nasal ventilation and duration of oxygen therapy. Complications included CLD (oxygen requirement at 36 weeks post-menstrual age), patent ductus arteriosus (PDA) ligation, severe intraventricular hemorrhage (IVH; Grade III or IV), periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), mortality, severe abdominal distension, feeding intolerance, and Edi catheter--associated complications such as gastric perforation or gastric bleeding.

This study complied with the standards of the Declaration of Helsinki and the current ethical guidelines, and was approved by the Institutional Ethics Board (protocol number: 1871). Written informed consent was obtained from the legally authorized representatives.

Results {#section7-2050312119838417}
=======

Within the study period, 27 preterm infants born at 28 (0/7) to 33 (6/7) weeks of gestation with RDS were admitted to our neonatal intensive care unit (NICU). Of these, 12 infants met one of the exclusion criteria (surfactant administration at \>2 h after birth, *n* = 5 patients; no respirator available for NIV-NAVA, *n* = 3; asphyxia, prolonged premature rupture of membranes, chylothorax, small for gestational age, *n* = 1 each). The remaining 15 infants were eligible for inclusion in the study.

Clinical characteristics of enrolled infants are presented in [Table 1](#table1-2050312119838417){ref-type="table"}. [Table 2](#table2-2050312119838417){ref-type="table"} shows the primary and secondary outcomes. Two of the 15 infants (13.3%) failed INSURE and received mechanical ventilation (one patient required mechanical ventilation for 4 days because of respiratory acidosis at 3 h after surfactant administration, and one patient required mechanical ventilation for 18 h because of respiratory acidosis at 4 h after surfactant administration). No infants experienced any major complications such as pneumothorax, PDA ligation, severe IVH (Grade III or IV), PVL, ROP, death, severe abdominal distension, feeding intolerance, gastric perforation, or gastric bleeding.

###### 

Subject characteristics.

![](10.1177_2050312119838417-table1)

                               Subjects (*N* = 15)   
  ---------------------------- --------------------- --------------
  Gestational age (weeks)      30                    (28.4--33.7)
  Birthweight (g)              1301                  (996--1870)
  Male                         5                     (33.3%)
  Antenatal glucocorticoid     1                     (6.7%)
  Maternal pregnancy disease   5                     (33.3%)
  Cesarean section delivery    15                    (100%)
  1-min Apgar score            6                     (3--8)
  5-min Apgar score            8                     (7--9)

Values are expressed as median (range) or number of subjects (percentage).

###### 

Study outcomes.

![](10.1177_2050312119838417-table2)

                                         Subjects (*N* = 15)   
  -------------------------------------- --------------------- ---------
  Primary outcome                                              
  INSURE failure                         2                     (13.3%)
  Secondary outcomes                                           
  Duration of nasal ventilation (days)   29                    (8--55)
  Duration of oxygen therapy (days)      1                     (0--10)
  Complications                                                
  O~2~ dependent at 36 weeks' PMA        0                     (0%)
  Pneumothorax                           0                     (0%)
  PDA ligation                           0                     (0%)
  Postnatal steroids                     0                     (0%)
  NEC                                    0                     (0%)
  IVH (Grade III or IV)                  0                     (0%)
  PVL                                    0                     (0%)
  ROP                                    0                     (0%)
  Death                                  0                     (0%)
  Severe abdominal distension            0                     (0%)
  Feeding intolerance                    0                     (0%)
  Gastric perforation                    0                     (0%)
  Gastric bleeding                       0                     (0%)

INSURE: INtubation-SURfactant-Extubation; PMA: post-menstrual age; PDA: patent ductus arteriosus; NEC: necrotizing enterocolitis; IVH: intraventricular hemorrhage; PVL: periventricular leukomalacia; ROP: retinopathy of prematurity.

Values are expressed as median (range) or number of subjects (percentage).

Discussion {#section8-2050312119838417}
==========

In this study, we made two important clinical observations. First, the rate of INSURE failure when NIV-NAVA was used after INSURE for preterm infants at 28 (0/7) to 33 (6/7) weeks of gestation with RDS was 13.3%. Second, NIV-NAVA can be safely used without complications such as pneumothorax, IVH, hypotension, severe abdominal distension, or Edi catheter--associated complications for preterm infants soon after birth.

Regarding the first observation, although the INSURE technique has been shown to decrease the incidence of subsequent mechanical ventilation and CLD, the rate of INSURE failure with NCPAP has been reported as 15% to 40%.^[@bibr1-2050312119838417][@bibr2-2050312119838417][@bibr3-2050312119838417][@bibr4-2050312119838417][@bibr5-2050312119838417][@bibr6-2050312119838417][@bibr7-2050312119838417]--[@bibr8-2050312119838417]^,^[@bibr10-2050312119838417][@bibr11-2050312119838417][@bibr12-2050312119838417]--[@bibr13-2050312119838417]^ Randomized controlled trials showed that non-synchronized NIPPV significantly decreased the incidence of INSURE failure (NIPPV: 11.4%--17% versus NCPAP: 20.9%--40%).^[@bibr10-2050312119838417][@bibr11-2050312119838417]--[@bibr12-2050312119838417]^ In addition, flow-SNIPPV has been reported to decrease breathing effort because of the effect in improving ventilator--patient interactions compared with NIPPV.^[@bibr14-2050312119838417]^ A retrospective cohort study showed that flow-SNIPPV compared with NCPAP significantly decreased the incidence of INSURE failure (flow-SNIPPV: 6.1% versus NCPAP: 35.5%).^[@bibr13-2050312119838417]^ NIV-NAVA is another mode of SNIPPV available for infants. NIV-NAVA was shown to improve patient--ventilator interactions even in infants with large air leak compared with flow-SNIPPV.^[@bibr15-2050312119838417]^ In this study, the rate of INSURE failure when NIV-NAVA was used for preterm infants with RDS was 13.3%, lower than that of NCPAP and comparable with that of NIPPV or flow-SNIPPV used after INSURE.

In terms of the second observation, NIV-NAVA is a new ventilator approach, and few reports have described its use among preterm infants.^[@bibr15-2050312119838417][@bibr16-2050312119838417][@bibr17-2050312119838417]--[@bibr18-2050312119838417]^ The finding that NIV-NAVA can be safely used without complications for preterm infants soon after birth is thus important. Asynchronous breathing in NIPPV may increase pneumothorax and fluctuation of blood pressure and brain blood flow. Good ventilator--patient interactions of NIV-NAVA^[@bibr15-2050312119838417]^ might be one reason why no severe complications associated with assisted ventilation (such as pneumothorax, IVH, hypotension, or severe abdominal distension) were encountered in this study.

There are some limitations of the study. First, it was the observational design, performed after introduction of both NIV-NAVA and INSURE at the same time. No historical controls were available to provide context on the efficacy of NIV-NAVA alone. Second, it was the small sample size of the study. Therefore, there was no gender balance (30% of infants were male), stratification analysis was impossible, and the range of the gestational age of the population studied was wide. Third, the sample size calculation was not performed. Because there was no report of the efficacy of NIV-NAVA used after INSURE for RDS in preterm infants, the estimated rate of INSURE failure which was necessary for sample size calculation was uncertain. Therefore, we conducted this research as a pilot study for larger analysis in the future to make a rough estimate of the rate of the INSURE failure of NIV-NAVA used after INSURE for RDS in preterm infants.

This study demonstrated that the rate of INSURE failure when NIV-NAVA was used after INSURE technique for preterm infants with RDS was 13.3%, and that NIV-NAVA was performed safely without severe complications for preterm infants soon after birth. Randomized controlled studies comparing NIV-NAVA with NCPAP or NIV-NAVA with flow-SNIPPV are needed to confirm the best respiratory support after INSURE for preterm infants with RDS. Moreover, further studies are needed to confirm the safety and efficacy of NIV-NAVA for extremely premature infants at less than 28 weeks of gestation. LISA (less invasive surfactant administration) is an alternative to INSURE and has been a common implementation in the neonatal units. Recent meta-analysis has shown the superiority of LISA to INSURE.^[@bibr19-2050312119838417]^ The study for evaluation of the efficacy of the combination of LISA and NIV-NAVA is also warranted.
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